Nouscom Poster Presentation Of Translational Phase 1 Data of NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Vaccine for the Treatment of MSI-H Solid Tumors, at AACR 2022
Nouscom Poster presentation at AACR 2022, reporting on new translational Phase 1 data illustrating how NOUS-209, an off-the-shelf neoantigen immunotherapy, with pembrolizumab for treatment of tumors characterized by microsatellite instability (MSI), induces robust T cell expansion and TCR diversification in patients demonstrating durable clinical responses. Proof of concept that vaccine-induced neoantigen-specific T cells in the periphery are able to infiltrate tumors post NOUS-209 treatment is shown.
- D’Alise AM et al., American Association for Cancer Research Annual Meeting (AACR) 2022.
Characterization of immune correlates of clinical activity for Nous-209, an off-the-shelf immunotherapy, with pembrolizumab for treatment of tumors characterized by microsatellite instability (MSI)